At this point, it's more [a matter of] the three players grabbing share from each other. We're not expecting the market to grow substantially. |
Dragging your 10-year-old to get a vaccine for a sexually transmitted disease could have some groups pretty upset. |
Generally, in order to get a [new] product up to peak revenues, it takes three or four years. In contrast, when something goes generic, it goes generic rather quickly. |
I think most of the biotech products are going to be safe for the rest of the decade. |
I think there's some people on the Street who are somewhat dissatisfied with his tenure at the moment, but don't think there's any immediate threat to his position. I think it's very difficult to keep people happy when your company goes through something like this. |
It seems like it's not really a major association, |
It was not your typical Pfizer conference call, |
It would be devastating. It is their biggest product by far. |
It's certainly a major medical need in the ability to prevent cervical cancer. That gives it the potential to be a blockbuster. We're not expecting a real quick ramp up on this, though it could become a billion dollar drug. |
Part of what people were worried about was that historically generic companies were successful in patent challenges about 75% of the time. We thought that couldn't continue, because they went after the easy patents first. [Friday's ruling shows] what's happening with the harder ones. |
People who are more science-oriented and innovative tend to look down on me-too drugs, ... there's a lot more risk in being innovative. |
Pfizer is becoming a value play. You're certainly not expecting a lot of growth in the future. |
That's not very impressive, because that's where your future is. |
The other drugs that came onto the market basically stole Viagra's share, ... The smaller the market, the more difficult it is to get another product. If you're the originator, you have a better chance of becoming the standard. |
The other drugs that came onto the market basically stole Viagra's share. The smaller the market, the more difficult it is to get another product. If you're the originator, you have a better chance of becoming the standard. |